Journal article
FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart
Martin L Ford, Edward R Smith, Laurie A Tomlinson, Prabal K Chatterjee, Chakravarthi Rajkumar, Stephen G Holt
Nephrology Dialysis Transplantation | OXFORD UNIV PRESS | Published : 2012
DOI: 10.1093/ndt/gfr316
Abstract
BACKGROUND: Extra-skeletal calcification and disordered phosphate metabolism are hallmarks of chronic kidney disease-mineral bone disorder (CKD-MBD). Osteoprotegerin (OPG) and fibroblast growth factor 23 (FGF-23) are increased in chronic kidney disease (CKD) and have been associated with arterial and cardiac dysfunction and reduced survival. Troponin T (cTnT) is released from cardiac myocytes under conditions of stress and is predictive of mortality across a range of renal functions. However, the utility of this biomarker was formerly limited by the lower limit of assay detection. The introduction of a high-sensitivity assay has enabled more detailed study of myocyte stress below the previou..
View full abstractGrants
Funding Acknowledgements
Allison Leslie is thanked for her assistance in measurement of APWV. Stephanie Goubet and Elizabeth Cheek are thanked for their statistical advice. This study was supported by the Department of Renal Medicine and the Clinical Investigation and Research Unit at BSUH NHS Trust.